Greg Doyle takes top job at Leading BioSciences as Straw moves aside

Lab work

San Diego’s Leading BioSciences gained a new leader today after making the biotech’s vet exec Greg Doyle CEO.

The clinical-stage biotech, which is working on targets aimed at the breakdown of the mucosal barrier, has appointed Doyle to take over from Clark Straw--who will remain as chairman of the board.

Doyle is no stranger to the company, being a long-standing member of Leading BioSciences' management team and board of directors, previously serving as chief operations officer and chief financial officer.

This completes its management shake-up that began back in March, when the company announced a slew of exec updates that saw Dr. Howard Dittrich (formerly of Laguna Pharmaceuticals) become its new chief medical advisor and Stephen Keane (previously president of CEO of Femta Pharmaceuticals) as its SVP of corporate development.

The biotech is currently working on drugs that target the breakdown of the intestinal mucosal barrier--a process believed to drive a range of serious health conditions in need of effective treatment options.

Phase II trials are underway for Leading BioSciences' investigational drug LB1148, which is supported by $22 million in foundational research backed by the National Institutes of Health. The biotech has high hopes for LB1148, which it believes can be applied to widespread conditions, including: acute shock, multiple organ failure, postoperative ileus and surgical adhesions.

"Greg has been a cornerstone of leadership at Leading BioSciences since the company's early days in 2010. He has driven a steady increase in shareholder value by leading the company's capital formation, operational maturity and team development, and helping to advance our lead drug candidate, LB1148, into Phase II clinical trials for multiple high-need indications," said Straw.

"Greg will continue to build on our founding vision to become the premier biopharmaceutical company focused on disease states caused by the mucosal barrier breakdown."

Doyle, serving as COO and CFO, led efforts to help the company raise over $20 million in private capital over the past 6 years.

-check out the release

Read more on

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.